Freshfields Guides AstraZeneca In $2.4B Pharma Co. Deal
AstraZeneca PLC said Tuesday that it will buy Fusion Pharmaceuticals, a biopharmaceutical company specializing in oncology, for up to $2.4 billion in cash to help it transform cancer treatments....To view the full article, register now.
Already a subscriber? Click here to view full article